胆汁酸通过S1PR-STAT3信号轴调节纤维化性胆管病中的调节性T细胞反应
该研究在小鼠硬化性胆管炎模型及130例胆道闭锁婴儿肝组织中,探索胆汁酸如何影响调节性T细胞(Treg)。单细胞分析显示胆汁酸通过S1P受体和STAT3促使Treg向Th17样表型转化并上调双调蛋白(AREG),抑制IBAT可增加Treg数量并减轻肝损伤和纤维化,诊断时Treg活化及AREG上调与2年自体肝生存改善相关。
要点
- 胆汁酸通过S1P受体和STAT3信号促使Treg获得Th17样转录程序并上调AREG。
- IBAT抑制剂升高肝内Treg数量,减轻Abcb4-/-小鼠肝损伤和纤维化,该保护作用在Treg清除或AREG中和后消失。
- 胆道闭锁婴儿诊断时肝转录谱显示Treg活化和AREG上调,与2年自体肝生存改善相关。
核心结论
- 胆汁酸通过促进Th17样表型抑制Treg的调节功能,从而限制其减轻免疫介导的胆管细胞损伤的能力。
- 恢复Treg功能和双调蛋白表达可能成为纤维化性胆管病的新治疗策略。
研究设计与样本
- 小鼠喂食含0.1% 3,5-二乙氧基羰基-1,4-二氢可力丁的饮食14天诱导硬化性胆管炎,随后普通饲料28天评估组织修复。
- 对连续肝细胞和核制备物进行单细胞RNA测序和ATAC-seq,定义胆汁淤积条件下控制Treg的基因调控网络。
- 在体外、三种小鼠硬化性胆管炎模型以及130例胆道闭锁婴儿肝组织样本中验证介导牛磺胆酸和鹅去氧胆酸对Treg作用的候选分子。
主要发现
- 单细胞分析显示Treg在胆汁淤积期间获得Th17样转录程序,并在修复阶段上调双调蛋白(Areg)。
- S1P受体被鉴定为牛磺胆酸和鹅去氧胆酸对Treg作用的中介物,并在体外和Abcb4-/-硬化性胆管炎模型中得到验证。
- 在CD4+细胞中敲除Stat3可增强胆管结扎后肝脏Treg反应。
- 使用IBAT抑制剂药物性降低肝脏胆汁酸浓度可增加Abcb4-/-小鼠肝脏Treg数量并减轻肝损伤和纤维化,该保护作用在Treg清除或AREG中和后消失。
- 在胆道闭锁婴儿中,诊断时与Treg活化和AREG上调一致的肝脏转录谱与2年自体肝生存改善相关。
临床怎么用
- 在实验模型中,通过IBAT抑制剂降低肝脏胆汁酸浓度、拮抗CD4+细胞中的STAT3或阻断S1P受体,可增强肝脏Treg反应并预防胆汁淤积性肝损伤。
- 这些临床前发现为纤维化性胆管病患者的未来临床试验提供了基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Regulatory T cells (Tregs), a subset of CD4 lymphocytes, protect against inflammatory tissue injury. However, it is currently unknown how retention of bile acids (BA) in fibrosing cholangiopathies like biliary atresia or PSC shape hepatic Treg responses. METHODS: To induce sclerosing cholangitis (SC), mice were fed a diet containing 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine for 14 days, followed by 28 days on regular chow to assess tissue repair. Serial hepatic cell and nuclear preparations were subjected to single-cell RNA sequencing and ATAC-seq to define gene regulatory networks controlling Tregs under cholestatic conditions. Candidate molecules mediating the effects of tauro- and chenodeoxycholic acid (T/CDCA) on Tregs were validated in vitro, across three murine models of SC, and in liver tissue samples from 130 infants with biliary atresia. RESULTS: Single-cell analyses revealed that Tregs acquired a Th17-like transcriptional program during cholestasis and upregulated amphiregulin (Areg) during the repair phase. S1P receptors were identified as mediators of T/CDCA effects on Tregs, and this was validated both in vitro and in the Abcb4-/- model of SC. Deletion of Stat3 in CD4+ cells enhanced hepatic Treg responses following bile duct ligation. Pharmacologic reduction of hepatic BA concentrations using an IBAT (ileal bile acid transporter) inhibitor increased hepatic Treg numbers and attenuated liver injury and fibrosis in Abcb4-/- mice. These protective effects were lost upon Treg depletion or AREG neutralization. Finally, in infants with biliary atresia, a liver transcriptional profile consistent with Treg activation and AREG upregulation at diagnosis was associated with improved 2-year native liver survival. CONCLUSION: Bile acids suppress Treg regulatory function by promoting a Th17-like phenotype, thereby limiting their capacity to mitigate immune-mediated cholangiocyte injury. Restoring Treg function and amphiregulin expression may represent a novel therapeutic strategy in fibrosing cholangiopathies. IMPACT AND IMPLICATIONS: In this study, we examined the role of CD4 lymphocytes in controlling bile duct epithelial injury in fibrosing cholangiopathies, with potential implications for developing targeted therapies for BA and PSC. Using single-cell genomics, functional assays, and complementary mouse models of sclerosing cholangitis, we investigated the mechanisms by which chenodeoxycholic acid-derived bile acids determine polarization and suppressor functions of CD4 lymphocytes. Interventions such as reducing hepatic bile acid concentrations with an IBAT (ileal bile acid transporter) inhibitor, antagonizing STAT3 in CD4+ cells, or blocking S1P receptors enhanced hepatic regulatory T cell responses and protected against cholestatic liver injury in experimental models. These preclinical findings provide a foundation for future clinical trials in patients with fibrosing cholangiopathies.
引用
- Kudira R, Yang ZF, Osuji I, et al. Bile acids engage the SIPR-STAT3 signaling axis to modulate regulatory T cell responses in fibrosing cholangiopathies. J Hepatol. 2025. PMID: 40545044. doi:10.1016/j.jhep.2025.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。